Anavex Life Sciences Corp (AVXL)

[XenaLives]

OUCH!

From your link:

We also included data on whether MCI subjects were on a regimen of AD medications (cholinesterase inhibitors and memantine), a factor shown to be associated with greater cognitive impairment and faster progression to dementia [34].

Publication referenced:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3259850/

Quote from the above:

Many patients with mild cognitive impairment (MCI) and mild Alzheimer disease(AD) participating in the National Institutes of Health (NIH) Alzheimer’s Disease Neuroimaging Initiative (ADNI)1 are receiving cholinesterase inhibitors (ChEIs) and memantine hydrochloride. The prescription of the former for MCI and the latter for mild AD is not approved by the US Food and Drug Administration (FDA). Rather, ChEIs are indicated for AD2 and memantine for moderate to severe AD (defined as AD with Mini-Mental State Examination [MMSE] scores below 15), per FDA-approved labeling.3

Clinical trial results do not show efficacy for ChEIs in MCI4–9 or for memantine in mild to moderate AD.10–14 In 1 placebo-controlled MCI trial,4 however, donepezil hydrochloride was associated with small effects on secondary outcomes, including memory and language subscales, as well as a clinical dementia rating(CDR)at12 to 18 months and an MMSE score at 24 months of treatment that were not maintained.

We compared MCI and AD patients enrolled in ADNI who were receiving ChEIs and memantine with those who were not receiving those medications on clinical differences at study entry and outcomes over 2 years to assess the medications’ potential for efficacy or for affecting clinical outcomes.